Bleeding complications in patients with squamous cell carcinoma of the head and neck.
Loading...
Embargo End Date
ICR Authors
Authors
Bergamini, C
Ferris, RL
Xie, J
Mariani, G
Ali, M
Holmes, WC
Harrington, K
Psyrri, A
Cavalieri, S
Licitra, L
Ferris, RL
Xie, J
Mariani, G
Ali, M
Holmes, WC
Harrington, K
Psyrri, A
Cavalieri, S
Licitra, L
Document Type
Journal Article
Date
2021-06-12
Date Accepted
2021-05-20
Abstract
Hemorrhage in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) may be attributed to chemotherapy and local tumor irradiation. Evidence of the relationship between hemorrhage in R/M HNSCC and targeted therapies, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors, or immune checkpoint inhibitors, is limited. We aimed to identify epidemiological and clinical data related to the occurrence of hemorrhage in R/M HNSCC and to explore its relationship with various therapies. We describe information obtained from literature searches as well as data extracted from a commercial database and a database from the author's institution (Istituto Nazionale dei Tumori of Milan). Evidence suggests that most bleeding events in R/M HNSCC are minor. Clinical trial safety data do not identify a causal association between hemorrhage and anti-EGFR agents or immune checkpoint inhibitors. In contrast, anti-VEGF agents are associated with increased, and often severe/fatal, hemorrhagic complications.
Citation
Head and Neck: journal for the sciences and specialities of the head and neck, 2021, 43 (9), pp. 2844 - 2858
Source Title
Head and Neck: journal for the sciences and specialities of the head and neck
Publisher
WILEY
ISSN
1043-3074
eISSN
1097-0347
1097-0347
1097-0347
Collections
Research Team
Targeted Therapy